VALNEVA SE

VLA | Paris Stock Exchange

Business Summary

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Country of Incorporation

France

Incorporation Date

1999-03-24

Business Sector

Pharmaceuticals & Medical Research

Company Address

6, Rue Alain Bombard

Get access to the below data and more business development tools by signing up for the MENA Company Data product.

- Ownership details

- Corporate structure

- Business classification

- Officers & Directors contact details

- Full company contact details

Find out more

Multiply your reach by contributing your content to LSEG

LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.

Find out more